Document Detail


Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program.
MedLine Citation:
PMID:  19661843     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Because of its cellular uptake pattern, ferumoxtran-10 may be potentially useful for the imaging of a variety of diseases (eg, atheroma, multiple sclerosis, stroke, renal graft rejection, glomerulonephritis and brain tumors, in addition to differentiation of metastatic and nonmetastatic lymph nodes). The aim of this article is to present a comprehensive review of the safety and tolerability of ferumoxtran-10 as reported during clinical development of the compound as an ultrasmall superparamagnetic iron oxide contrast agent for use in magnetic resonance imaging. MATERIALS AND METHODS: The safety profile of ferumoxtran-10 was assessed using pooled data from 37 phase I to III clinical studies in 1777 adults (1663 received the contrast agent [1527 patients and 136 healthy volunteers], 75 received placebo, and 39 patients were enrolled but did not receive study medication). RESULTS: At least one adverse event was reported in 23.2% of patients who received ferumoxtran-10. Adverse events were of mild-to-moderate severity in 86.3% of patients in the ferumoxtran-10 group. At least 1 event considered by the investigator to be related to study treatment was reported in 18.2% of patients in the ferumoxtran-10 group. The most commonly reported treatment-related adverse events were back pain, pruritus, headache, and urticaria. A total of 44 patients (2.6%) in the ferumoxtran-10 group reported 76 serious adverse event (SAE). Only 7 SAEs (0.42%) were considered to be treatment-related (anaphylactic shock, chest pain, dyspnea, skin rash, oxygen saturation decreased, and 2 cases of hypotension). There were 12 deaths, only one of which (anaphylactic shock) was considered to be related to ferumoxtran-10 which was administered by bolus injection of undiluted product, a mode of administration that is no longer recommended. Results in high-risk groups of patients including the elderly and those with hepatic, renal or cardiovascular disease seemed to show no cause for special clinical concern in these groups. CONCLUSIONS: Clinical experience to date therefore shows ferumoxtran-10 to be a well tolerated contrast agent.
Authors:
Hamm Bernd; Eric De Kerviler; Sophie Gaillard; Bruno Bonnemain
Related Documents :
21072153 - Percutaneous real-time ultrasound-guided renal biopsy performed solely by nephrologists...
17311833 - Efficacy and safety of 'rescue therapy' with mycophenolate mofetil in resistant primary...
23478743 - Effect of aliskiren on postdischarge mortality and heart failure readmissions among pat...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Investigative radiology     Volume:  44     ISSN:  1536-0210     ISO Abbreviation:  Invest Radiol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-08-07     Completed Date:  2009-10-28     Revised Date:  2009-12-02    
Medline Journal Info:
Nlm Unique ID:  0045377     Medline TA:  Invest Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  336-42     Citation Subset:  IM    
Affiliation:
Department of Radiology, Universitätsklinikum Charite, Medizinische Fakultät der Humboldt-Universität zu Berlin, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Contrast Media / adverse effects*
Dextrans / adverse effects*,  diagnostic use*
Female
Ferrosoferric Oxide / adverse effects*,  diagnostic use*
Humans
Male
Chemical
Reg. No./Substance:
0/Contrast Media; 0/ferumoxtran-10; 1317-61-9/Ferrosoferric Oxide; 9004-54-0/Dextrans

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence and correlates of HIV testing among sexually active African American adolescents in 4 US ...
Next Document:  Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer.